High-dose Methotrexate

Phase 3

High-dose Methotrexate is one of 23 therapeutic programs targeting Metastatic Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Breast CancerRecruiting

Extranodal NK T Cell LymphomaNot yet recruiting

Osteosarcoma in ChildrenNot yet recruiting

Metastatic Breast CancerPhase 2

Recruiting

Extranodal NK T Cell LymphomaPhase 3

Not yet recruiting

Osteosarcoma in ChildrenPhase 2

Not yet recruiting

Competition

Competitive Landscape

27 competitors in Metastatic Breast Cancer

#DrugCompanyPhaseTrials

Kisqali

Novartis

Approved

3 2

Nolvadex

AstraZeneca

Approved

1 3

Femara

Novartis

Approved

1 4

Faslodex

FFresenius Kabi Oncology Ltd.

Approved

3 5

Zoladex

TTerSera Therapeutics LLC

Approved

1 6

Arimidex

IIstituto Clinico Humanitas

Approved

1 7

Ibrance

Pfizer

Phase 3

3 8

Fotivda

Roche

Phase 3

1 9

Aromasin

Pfizer

Phase 2

1 10

Afinitor

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Metastatic Breast Cancer

NCT02422641

Q4 2028

Phase 2Not yet recruiting

Osteosarcoma in Children

NCT07560826

Q4 2031

Phase 3Not yet recruiting

Extranodal NK T Cell Lymphoma

NCT07678229

Clinical

Trials by Indication[1]

Metastatic Breast Cancer1 trial

Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Controlled Trail

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT02422641·16 enrolled

Extranodal NK T Cell Lymphoma1 trial

BRIDGE-NK: A Randomized, Open-Label, Prospective Phase III Study of Immunotherapy Induction Versus Chemotherapy Induction Followed by Autologous Hematopoietic Stem Cell Transplantation Consolidation in Newly Diagnosed Advanced Extranodal NK/T-Cell Lymphoma

Not yet recruiting·RRong Tao·Phase 3·NCT07678229·150 enrolled

Osteosarcoma in Children1 trial

The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma

Not yet recruiting·WWake Forest University Health Sciences·Phase 2·NCT07560826·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for High-dose Methotrexate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for High-dose Methotrexate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: WWake Forest University Health Sciences

High-dose Methotrexate

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Q4 2031

Trials by Indication[1]

Metastatic Breast Cancer1 trial

Extranodal NK T Cell Lymphoma1 trial

Osteosarcoma in Children1 trial

References

Drug Info

Quick Facts

Related News